Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Swain, S. M.
Right arrow Articles by Gams, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swain, S. M.
Right arrow Articles by Gams, R. A.

Journal of Clinical Oncology, Vol 15, 1318-1332, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer

SM Swain, FS Whaley, MC Gerber, S Weisberg, M York, D Spicer, SE Jones, S Wadler, A Desai, C Vogel, J Speyer, A Mittelman, S Reddy, K Pendergrass, E Velez- Garcia, MS Ewer, JR Bianchine and RA Gams
Comprehensive Breast Center, Washington, DC 20015-2034, USA. swainsm@aol.com

PURPOSE: To determine the cardioprotective effect of dexrazoxane (DZR) used in a doxorubicin-based combination therapy in advanced breast cancer. PATIENTS AND METHODS: Between November 1988 and January 1991, 534 patients with advanced breast cancer were randomized to two multicenter, double-blind studies (088001 and 088006). Patients received fluorouracil, doxorubicin, and cyclophosphamide (FAC) with either DZR (DZR-to-doxorubicin ratio, 10:1) or placebo (PLA) every 3 weeks and were monitored with serial multiplegated acquisition (MUGA) scans. RESULTS: The hazards ratio (HR) of PLA to DZR for a cardiac event, which was predefined ejection fraction changes or congestive heart failure (CHF), was 2.63 (95% confidence interval [CI], 1.61 to 4.27; P < .001) for 088001 and 2.00 (95% CI, 1.01 to 3.96; P = .038) for 088006. The objective response rates for 088001 were 46.8% for DZR and 60.5% for PLA, a difference of 14% (95% CI, -25% to -2%; P = .019), and for 088006 were 53.7% for DZR and 49.3% for PLA, a difference of 4% (95% CI, -13% to 22%; P = .63). Time to progression and survival were not significantly different between treatment arms in either study. Toxicities on the DZR arms included lower granulocyte and platelet counts at nadir (P = .009 and P = .004, respectively) and more pain on injection (P = .001), with no difference in the rates of fever, infection, or hemorrhage. CONCLUSION: DZR had a significant cardioprotective effect as measured by noninvasive testing and clinical CHF. One of the two studies (088001) showed a lower response rate with DZR, but time to progression and survival were not significantly different. DZR is the first agent shown to reduce cardiotoxicity from doxorubicin.


This article has been cited by other articles:


Home page
 Journal of Pharmacy PracticeHome page
B. L. Frei and S. A. Soefje
A Review of the Cardiovascular Effects of Oncology Agents
Journal of Pharmacy Practice, April 1, 2008; 21(2): 146 - 158.
[Abstract] [PDF]

Home page
 JCOHome page
E. V. Barry, L. M. Vrooman, S. E. Dahlberg, D. S. Neuberg, B. L. Asselin, U. H. Athale, L. A. Clavell, E. C. Larsen, A. Moghrabi, Y. Samson, et al.
Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane
J. Clin. Oncol., March 1, 2008; 26(7): 1106 - 1111.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. R.J. H. Bird and S. M. Swain
Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems
Clin. Cancer Res., January 1, 2008; 14(1): 14 - 24.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
E. V. Barry, S. E. Lipshultz, and S. E. Sallan
Anthracycline-induced Cardiotoxicity: Natural History, Risk Factors, and Prevention
ASCO Educational Book, January 1, 2008; 2008(1): 448 - 453.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
S. K. Bjelogrlic, J. Radic, S. Radulovic, M. Jokanovic, and V. Jovic
Effects of Dexrazoxane and Amifostine on Evolution of Doxorubicin Cardiomyopathy In Vivo
Experimental Biology and Medicine, December 1, 2007; 232(11): 1414 - 1424.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. L. Schwartz, L. S. Constine, W. B. London, R. Sposto, D. L. Friedman, C. K. Tebbi, N. Mendenhall, A. R. Chen, P. A. de Alarcon, D. Villaluna, et al.
In Reply
J. Clin. Oncol., October 10, 2007; 25(29): 4690 - 4691.
[Full Text] [PDF]

Home page
 JCOHome page
J. R. Carver, C. L. Shapiro, A. Ng, L. Jacobs, C. Schwartz, K. S. Virgo, K. L. Hagerty, M. R. Somerfield, D. J. Vaughn, and for the ASCO Cancer Survivorship Expert Panel
American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects
J. Clin. Oncol., September 1, 2007; 25(25): 3991 - 4008.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. C. Portera and S. M. Swain
The Heart of the Matter
J. Clin. Oncol., September 1, 2007; 25(25): 3794 - 3796.
[Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
L. B. Michaud, J. P. Karpinski, K. L. Jones, and J. Espirito
Dietary supplements in patients with cancer: Risks and key concepts, part 1
Am. J. Health Syst. Pharm., February 15, 2007; 64(4): 369 - 381.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. K. Tebbi, W. B. London, D. Friedman, D. Villaluna, P. A. De Alarcon, L. S. Constine, N. P. Mendenhall, R. Sposto, A. Chauvenet, and C. L. Schwartz
Dexrazoxane-Associated Risk for Acute Myeloid Leukemia/Myelodysplastic Syndrome and Other Secondary Malignancies in Pediatric Hodgkin's Disease
J. Clin. Oncol., February 10, 2007; 25(5): 493 - 500.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Moghrabi, D. E. Levy, B. Asselin, R. Barr, L. Clavell, C. Hurwitz, Y. Samson, M. Schorin, V. K. Dalton, S. E. Lipshultz, et al.
Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia
Blood, February 1, 2007; 109(3): 896 - 904.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Sterba, O. Popelova, T. Simunek, Y. Mazurova, A. Potacova, M. Adamcova, H. Kaiserova, P. Ponka, and V. Gersl
Cardioprotective Effects of a Novel Iron Chelator, Pyridoxal 2-Chlorobenzoyl Hydrazone, in the Rabbit Model of Daunorubicin-Induced Cardiotoxicity
J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1336 - 1347.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Marty, M. Espie, A. Llombart, A. Monnier, B. L. Rapoport, V. Stahalova, and On behalf of the Dexrazoxane Study Group
Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane(R)) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy
Ann. Onc., April 1, 2006; 17(4): 614 - 622.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Burdette-Radoux and H. B. Muss
Adjuvant chemotherapy in the elderly: whom to treat, what regimen?
Oncologist, March 1, 2006; 11(3): 234 - 242.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. D. Floyd, D. T. Nguyen, R. L. Lobins, Q. Bashir, D. C. Doll, and M. C. Perry
Cardiotoxicity of Cancer Therapy
J. Clin. Oncol., October 20, 2005; 23(30): 7685 - 7696.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
X. Xu, H. L. Persson, and D. R. Richardson
Molecular Pharmacology of the Interaction of Anthracyclines with Iron
Mol. Pharmacol., August 1, 2005; 68(2): 261 - 271.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
X. Peng, B. Chen, C. C. Lim, and D. B. Sawyer
The Cardiotoxicology of Anthracycline Chemotherapeutics: TRANSLATING MOLECULAR MECHANISM INTO PREVENTATIVE MEDICINE
Mol. Interv., June 1, 2005; 5(3): 163 - 171.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. F. Hofland, A. V. Thougaard, M. Sehested, and P. B. Jensen
Dexrazoxane Protects against Myelosuppression from the DNA Cleavage-Enhancing Drugs Etoposide and Daunorubicin but not Doxorubicin
Clin. Cancer Res., May 15, 2005; 11(10): 3915 - 3924.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. Hequet, Q.H. Le, I. Moullet, E. Pauli, G. Salles, D. Espinouse, C. Dumontet, C. Thieblemont, P. Arnaud, D. Antal, et al.
Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults
J. Clin. Oncol., May 15, 2004; 22(10): 1864 - 1871.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Bianchi, J. Albanell, W. Eiermann, G. Vitali, D. Borquez, L. Vigano, R. Molina, G. Raab, A. Locatelli, B. Vanhauwere, et al.
Pilot Trial of Trastuzumab Starting with or after the Doxorubicin Component of a Doxorubicin plus Paclitaxel Regimen for Women with HER2-Positive Advanced Breast Cancer
Clin. Cancer Res., December 1, 2003; 9(16): 5944 - 5951.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Campos
Liposomal Anthracyclines: Adjuvant and Neoadjuvant Therapy for Breast Cancer
Oncologist, August 1, 2003; 8(90002): 10 - 16.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Limat, K. Demesmay, L. Voillat, Y. Bernard, E. Deconinck, A. Brion, A. Sabbah, M. C. Woronoff-Lemsi, and J. Y. Cahn
Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma
Ann. Onc., February 1, 2003; 14(2): 277 - 281.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. H. Giordano, D. J. Booser, J. L. Murray, N. K. Ibrahim, Z. U. Rahman, V. Valero, R. L. Theriault, M. F. Rosales, E. Rivera, D. Frye, et al.
A Detailed Evaluation of Cardiac Toxicity: A Phase II Study of Doxorubicin and One- or Three-Hour-Infusion Paclitaxel in Patients with Metastatic Breast Cancer
Clin. Cancer Res., November 1, 2002; 8(11): 3360 - 3368.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. M. Schuchter, M. L. Hensley, N. J. Meropol, and E. P. Winer
2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology
J. Clin. Oncol., June 15, 2002; 20(12): 2895 - 2903.
[Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
G. N Hortobagyi
Progress in Systemic Chemotherapy of Primary Breast Cancer: an Overview
J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 72 - 79.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Williams, P. Cortazar, R. Pazdur, G. Batist, and L. Welles
Developing Drugs to Decrease the Toxicity of Chemotherapy
J. Clin. Oncol., July 15, 2001; 19(14): 3439 - 3441.
[Full Text]

Home page
 Clin. Cancer Res.Home page
M. L. Tetef, T. W. Synold, W. Chow, L. Leong, K. Margolin, R. Morgan, J. Raschko, S. Shibata, G. Somlo, Y. Yen, et al.
Phase I Trial of 96-Hour Continuous Infusion of Dexrazoxane in Patients with Advanced Malignancies
Clin. Cancer Res., June 1, 2001; 7(6): 1569 - 1576.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Batist, G. Ramakrishnan, C. S. Rao, A. Chandrasekharan, J. Gutheil, T. Guthrie, P. Shah, A. Khojasteh, M. K. Nair, K. Hoelzer, et al.
Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer
J. Clin. Oncol., March 1, 2001; 19(5): 1444 - 1454.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. C.M. Kremer, E. C. van Dalen, M. Offringa, J. Ottenkamp, and P. A. Voute
Anthracycline-Induced Clinical Heart Failure in a Cohort of 607 Children: Long-Term Follow-Up Study
J. Clin. Oncol., January 1, 2001; 19(1): 191 - 196.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Sparano, A. O'Neill, P. L. Schaefer, C. I. Falkson, and W. C. Wood
Phase II Trial of Doxorubicin and Docetaxel Plus Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer: Eastern Cooperative Oncology Group Study E1196
J. Clin. Oncol., June 12, 2000; 18(12): 2369 - 2377.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Hellmann, M. L. Hensley, L. M. Schuchter, E. P. Winer, N. J. Meropol, and D. Pfister
Dexrazoxane and the ASCO Guidelines for the Use of Chemotherapy and Radiotherapy Protectants: A Critique
J. Clin. Oncol., May 9, 2000; 18(9): 2004 - 2006.
[Full Text]

Home page
 Clin. Cancer Res.Home page
F. A. A. van Acker, S. A. B. E. van Acker, K. Kramer, G. R. M. M. Haenen, A. Bast, and W. J. F. van der Vijgh
7-Monohydroxyethylrutoside Protects against Chronic Doxorubicin-induced Cardiotoxicity When Administered Only Once Per Week
Clin. Cancer Res., April 1, 2000; 6(4): 1337 - 1341.
[Abstract] [Full Text]

Home page
 JCOHome page
J. A. Sparano, P. Hu, R. M. Rao, C. I. Falkson, A. C. Wolff, and W. C. Wood
Phase II Trial of Doxorubicin and Paclitaxel Plus Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer: An Eastern Cooperative Oncology Group Study
J. Clin. Oncol., December 1, 1999; 17(12): 3828 - 3834.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
S. Chen, M. Garami, and D. G. Gardner
Doxorubicin Selectively Inhibits Brain Versus Atrial Natriuretic Peptide Gene Expression in Cultured Neonatal Rat Myocytes
Hypertension, December 1, 1999; 34(6): 1223 - 1231.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
K Hellmann
Preventing the cardiotoxicity of anthracyclines by dexrazoxane
BMJ, October 23, 1999; 319(7217): 1085 - 1086.
[Full Text]

Home page
 JCOHome page
M. L. Hensley, L. M. Schuchter, C. Lindley, N. J. Meropol, G. I. Cohen, G. Broder, W. J. Gradishar, D. M. Green, R. J. Langdon Jr, R. B. Mitchell, et al.
American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants
J. Clin. Oncol., October 1, 1999; 17(10): 3333 - 3355.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. Valero, A. U. Buzdar, R. L. Theriault, N. Azarnia, G. A. Fonseca, J. Willey, M. Ewer, R. S. Walters, B. Mackay, D. Podoloff, et al.
Phase II Trial of Liposome-Encapsulated Doxorubicin, Cyclophosphamide, and Fluorouracil as First-Line Therapy in Patients With Metastatic Breast Cancer
J. Clin. Oncol., May 1, 1999; 17(5): 1425 - 1425.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. Klein and F. M. Muggia
Cytoprotection: Shelter from the Storm
Oncologist, April 1, 1999; 4(2): 112 - 121.
[Full Text]

Home page
 JCOHome page
J. A. Sparano, J. Speyer, W. J. Gradishar, L. Liebes, R. Sridhara, S. Mendoza, D. Fry, and M. J. Egorin
Phase I Trial of Escalating Doses of Paclitaxel Plus Doxorubicin and Dexrazoxane in Patients With Advanced Breast Cancer
J. Clin. Oncol., March 1, 1999; 17(3): 880 - 880.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. E. Lipshultz, M. A. Grenier, S. D. Colan, A. D. Ginsburg, S. M. Swain, F. M. Muggia, J. L. Speyer, P. K. Singal, C. L.M. Olweny, and T. Li
Doxorubicin-Induced Cardiomyopathy
N. Engl. J. Med., February 25, 1999; 340(8): 653 - 655.
[Full Text]

Home page
 Drug Metab. Dispos.Home page
B. B. Hasinoff and R. G. Aoyama
Relative Plasma Levels of the Cardioprotective Drug Dexrazoxane and Its Two Active Ring-Opened Metabolites in the Rat
Drug Metab. Dispos., February 1, 1999; 27(2): 265 - 268.
[Abstract] [Full Text]

Home page
 FASEB J.Home page
G. MINOTTI, G. CAIRO, and E. MONTI
Role of iron in anthracycline cardiotoxicity: new tunes for an old song?
FASEB J, February 1, 1999; 13(2): 199 - 212.
[Abstract] [Full Text]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1997 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online